Website Logo

Press

Keep up-to-date with relevant news, important announcements and key market insights.

READ MORE
FEATURED

Bionical Emas sells EMAS Pharma to Kester Capital following strategic review

About Bionical Emas

Bionical Emas is the only Contract Research Organization that combines Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) to deliver a unique, seamless approach to bring life-changing medicines to patients around the world.

Learn more
READ MORE

Bionical Emas sells EMAS Pharma to Kester Capital following strategic review

READ MORE

Kester Capital backs experienced management team in acquiring EMAS Pharma

READ MORE

Bionical Emas is recognized as one of the UK’s Best Workplaces in BioPharma™!

READ MORE

Charity of the Year 2024 – The Dream Factory

READ MORE

The Guardian - Partnering with patients on their rare disease journey

READ MORE

Women in Healthcare - PharmaTimes May 2023

READ MORE

The Guardian - Inviting patients as equal partners in the drug development process

READ MORE

Tom Watson appointed Chief Executive Officer

READ MORE

Women in Healthcare - PharmaTimes May 2022

READ MORE

Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035

READ MORE

Bionical Emas to establish European storage, distribution and labelling facility in Co. Westmeath

READ MORE

Women in Healthcare - PharmaTimes May 2021

How else can we help?

Discover more about the services and capabilities Bionical Emas has to offer

READ MORE

Clinical Development

READ MORE

Clinical Trial Supply

READ MORE

Early Access Programs